GlassScriptPhysician profile
Clara Barranco
NPI 1780204057
$8,128.17
in general payments reported to CMS, 2019-2025
24 companies · $2,299 in 2025
The $2,299 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $601 · 2022: $1,696 · 2023: $1,419 · 2024: $2,113 · 2025: $2,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,642 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,641.91 |
| Education | $188.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,852.11 | 2021-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $847.33 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $750.76 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $724.02 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $655.88 | 2021-2025 | |
| Janssen Biotech, INC. | $406.62 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Hill Dermaceuticals, INC. | $380.92 | 2025 | Tolak |
| Lilly USA, LLC | $362.31 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Incyte Corporation | $355.24 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $325.41 | 2022-2025 | Sotyktu |
| Pfizer INC. | $325.36 | 2024-2025 | |
| Galderma Laboratories, L.P. | $263.71 | 2022-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $207.89 | 2024-2025 | |
| Amgen INC. | $162.67 | 2024-2025 | Otezla, Otezla |
| Leo Pharma INC. | $143.98 | 2024-2025 | Adbry, Anzupgo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $138.42 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $60.59 | 2024-2025 | Zoryve |
| Biofrontera INC. | $40.39 | 2025 | Ameluz |
| Organogenesis INC. | $38.79 | 2024-2025 | Apligraf |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.37 | 2025 | Cabtreo |
| Verrica Pharmaceuticals INC. | $18.58 | 2024 | Ycanth |
| Krystal Biotech INC | $18.22 | 2024 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.29 | 2023 | Spevigo |
| Regeneron Pharmaceuticals, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Barranco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.